The results of this study indicated that entrectinib is an attractive candidate for suppressing multiple target genes and thereby modulating VEGFR2, β-catenin, ERK, AKT, and NFκB signaling and EMT in GC patients with amplification of NTRK1-3 and VEGFR2. Here, KDR is linked to gastric cancer.